Physician profile
Bryce A Meredith
NPI 1578971800
$1,044.81
in general payments reported to CMS, 2019-2025
19 companies · $23.29 in 2025
The $23.29 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $120 · 2021: $82.02 · 2022: $454 · 2023: $71.26 · 2024: $79.98 · 2025: $23.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $236.13 | 2020-2023 | Farxiga |
| Lilly USA, LLC | $195.73 | 2019-2022 | |
| Novo Nordisk INC | $101.41 | 2019-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $81.67 | 2019-2022 | |
| Pacira Therapeutics, INC. | $73.77 | 2019-2020 | |
| Bone Support INC. | $56.98 | 2024 | Cerament G, Ceramentbone Void Filler |
| Abbvie INC. | $50.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.66 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $36.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.28 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $23.29 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $23.00 | 2024 | Exparel, Iovera, Zilretta |
| Depuy Synthes Sales INC. | $18.80 | 2022 | |
| Amgen INC. | $16.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.50 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.60 | 2020 | |
| Zyla Life Sciences, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.